Terry Chrisomalis | TalkMarkets | Page 3

Terry Chrisomalis

Contributor's Links: Biotechpicklist SeekingAlpha
I am a graduate of Business Administration and have created my own Pharmaceutical website "BiotechPicklist.com". I have been investing and writing about biotechnology stocks for 5 years now and have extensive experience writing about the science and companies themselves. I am a Seeking ...more
Following: 31 Followers: 123

Articles

Latest Posts
33 to 48 of 55 Posts
<<< 1 2 3 4 >>>
Opko Health Posts Positive Phase 3 Results For Its Rayaldee Drug
Wednesday, August 13, 2014 5:10 PM EDT
Opko Health Achieves Positive Phase 3 Results for Chronic Kidney Disease
In this article: OPK, RXII
Read
Two Biotech Stocks To Consider For Ebola Virus
Wednesday, August 6, 2014 12:32 PM EDT
Lately, everyday when people wake up, they hear news about a new Ebola case in various parts of the world and that the spread of the virus is continuing everywhere around the globe.
In this article: TKMR, SRPT
Read
Galectin Therapeutics Gets Punished For Phase 1 Trial, But Wall Street Misses The Point
Tuesday, July 29, 2014 10:44 PM EDT
Galectin Still has long term opportunity in fatty liver disease with final cohort 3 trial.
In this article: GALT
Read
Inovio Pharmaceuticals Posts Positive Phase 2 Cervical Dysplasia Data, Platform Now Validated
Wednesday, July 23, 2014 11:47 AM EDT
Inovio rises on Positive phase 2 data for Cervical Dysplasia.
In this article: INO, RHHBY
Read
Puma Biotechnology Surges 200% After Positive Results For Breast Cancer Drug
Wednesday, July 23, 2014 2:33 AM EDT
Puma Biotechnology Surges 200% after Positive Phase 3 Results
In this article: RHHBY, ICPT, PBYI
Read
Sarepta Tumbles On New Drug Data But Presents A Big Buying Opportunity
Monday, July 14, 2014 3:25 PM EDT
Shares of Sarepta Therapeutics (SRPT) tumbled as much as 28% after it updated its phase 2b data from its Eteplirsen study. But the stock fell for the wrong reasons and should still be a strong buy. Here's why...
In this article: RNA, SRPT
Read
Why I'm Still Long Rxi Pharmaceuticals After Recent Developments
Wednesday, July 9, 2014 11:01 AM EDT
Rxi Pharmaceuticals provides a huge opportunity with impending phase 2 catalyst
In this article: OPK, REGN, RXII
Read
FDA Approves Mannkind’s Afrezza, A Better Case For Patients With Diabetes
Monday, June 30, 2014 1:27 PM EDT
FDA approval for Afrezza was a major hurdle for Mannkind
In this article: MNKD
Read
Vertex Pharmaceuticals Creates Combo Magic For Cystic Fibrosis Patients
Tuesday, June 24, 2014 6:21 PM EDT
Vertex soars 40% on its combination drug for Cystic Fibrosis.
In this article: VRTX
Read
Isis Pharmaceuticals Shows Positive Results In Patients With Type 2 Diabetes
Monday, June 16, 2014 7:28 PM EDT
Isis Pharmaceuticals leads the way in diabetes utilizing RNA antisense technology
In this article: ISIS, BIIB
Read
Orexigen Gets An Early Morning Surprise With FDA Delay For Contrave
Wednesday, June 11, 2014 8:58 AM EDT
The FDA issued a delay for Orexigen's (OREX) obesity drug Contrave, The stock has now fallen by more than 15% in pre-market trading, creating an investment opportunity for patient investors.
In this article: ARNA, OREX, VVUS
Read
Achillion Surges As FDA Releases Hepatitis C Clinical Hold On Sovaprevir
Tuesday, June 10, 2014 11:27 AM EDT
Achillion surges 52% in one day due to the news of the FDA releasing clinical hold.
In this article: BMY, GSK, MRK, PFE, ACHN
Read
Merck Felt Lonely In The Hepatitis C Space, Acquired Idenix Pharmaceuticals
Monday, June 9, 2014 8:26 PM EDT
Today Merck paid $3.8 billion dollars to acquire Idenix Pharmaceuticals (IDIX) or $24.50 per share. Why would Merck want to acquire Idenix Pharmaceuticals if Gilead's Sovalid is already in the race and gaining a huge chunk of the Hepatitis C market? It had a good reason...
In this article: MRK, IDIX, GILD
Read
Rxi Pharmaceuticals Jefferies Presentation Gives Insight For Future
Tuesday, June 3, 2014 3:53 PM EDT
Rxi Pharmaceutical's Presentation Offers New Insights Into Trials. Investors should take notice of this company, as it offers a chance for patients to get treatments for unmet medical needs.
In this article: RXII
Read
Clovis Oncology Slides Despite Positive Lung Cancer Data Presented At ASCO 2014
Tuesday, June 3, 2014 10:26 AM EDT
Clovis Oncology released impressive results showing that the cancer in 90% of test patients taking its CO-1686 did not progress further or regressed. Yet CLVS is currently tumbling by 13%. Why? Clovis failed to disclose that it also caused in increase in diabetes. AstraZeneca's ompound does not.
In this article: AZN, CLVS
Read
OncoSec Impresses With Phase 2 Melanoma Results At ASCO 2014
Monday, June 2, 2014 8:34 PM EDT
OncoSec Shows Positive Phase 2 Interim Results in Advanced Melanoma at ASCO 2014 creating an exciting investment opportunity for both short term traders and long term buyers.
In this article: INO, ONCS
Read
33 to 48 of 55 Posts
<<< 1 2 3 4 >>>